Literature DB >> 32868330

Cefiderocol Resistance in Acinetobacter baumannii: Roles of β-Lactamases, Siderophore Receptors, and Penicillin Binding Protein 3.

Saquib Malik1, Monica Kaminski1, David Landman1, John Quale2.   

Abstract

Cefiderocol is a siderophore cephalosporin active against many multidrug-resistant (MDR) Gram-negative pathogens. We examined the resistance mechanisms in 12 Acinetobacter baumannii strains with cefiderocol MICs ranging from ≤0.03 to >32 μg/ml. Cefiderocol resistance could not be explained by β-lactamase activity. Cefiderocol resistance was associated with reduced expression of the siderophore receptor gene pirA Mutations involving PBP3 may have contributed to resistance in one strain. Additional studies are needed to assess the role of other siderophore receptors.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  Acinetobacterzzm321990; siderophore

Year:  2020        PMID: 32868330      PMCID: PMC7577126          DOI: 10.1128/AAC.01221-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

Review 1.  TonB-dependent receptors-structural perspectives.

Authors:  Andrew D Ferguson; Johann Deisenhofer
Journal:  Biochim Biophys Acta       Date:  2002-10-11

2.  In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).

Authors:  Krystyna M Kazmierczak; Masakatsu Tsuji; Mark G Wise; Meredith Hackel; Yoshinori Yamano; Roger Echols; Daniel F Sahm
Journal:  Int J Antimicrob Agents       Date:  2018-10-26       Impact factor: 5.283

3.  Structure and Function of the PiuA and PirA Siderophore-Drug Receptors from Pseudomonas aeruginosa and Acinetobacter baumannii.

Authors:  Lucile Moynié; Alexandre Luscher; Dora Rolo; Daniel Pletzer; Antoni Tortajada; Helge Weingart; Yvonne Braun; Malcolm G P Page; James H Naismith; Thilo Köhler
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

Review 4.  New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections.

Authors:  Burcu Isler; Yohei Doi; Robert A Bonomo; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

5.  ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum β-Lactamases and Carbapenemases.

Authors:  Michael R Jacobs; Ayman M Abdelhamed; Caryn E Good; Daniel D Rhoads; Kristine M Hujer; Andrea M Hujer; T Nicholas Domitrovic; Susan D Rudin; Sandra S Richter; David van Duin; Barry N Kreiswirth; Chris Greco; Derrick E Fouts; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

6.  Involvement of Fe uptake systems and AmpC β-lactamase in susceptibility to the siderophore monosulfactam BAL30072 in Pseudomonas aeruginosa.

Authors:  Christian van Delden; Malcolm G P Page; Thilo Köhler
Journal:  Antimicrob Agents Chemother       Date:  2013-02-19       Impact factor: 5.191

7.  Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.

Authors:  Simona Bratu; David Landman; Don Antonio Martin; Claudiu Georgescu; John Quale
Journal:  Antimicrob Agents Chemother       Date:  2008-06-30       Impact factor: 5.191

8.  In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria.

Authors:  Akinobu Ito; Naoki Kohira; Samuel K Bouchillon; Joshua West; Stephen Rittenhouse; Helio S Sader; Paul R Rhomberg; Ronald N Jones; Hidenori Yoshizawa; Rio Nakamura; Masakatsu Tsuji; Yoshinori Yamano
Journal:  J Antimicrob Chemother       Date:  2015-12-07       Impact factor: 5.790

9.  Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis.

Authors:  Evelina Tacconelli; Elena Carrara; Alessia Savoldi; Stephan Harbarth; Marc Mendelson; Dominique L Monnet; Céline Pulcini; Gunnar Kahlmeter; Jan Kluytmans; Yehuda Carmeli; Marc Ouellette; Kevin Outterson; Jean Patel; Marco Cavaleri; Edward M Cox; Chris R Houchens; M Lindsay Grayson; Paul Hansen; Nalini Singh; Ursula Theuretzbacher; Nicola Magrini
Journal:  Lancet Infect Dis       Date:  2017-12-21       Impact factor: 71.421

10.  The Phyre2 web portal for protein modeling, prediction and analysis.

Authors:  Lawrence A Kelley; Stefans Mezulis; Christopher M Yates; Mark N Wass; Michael J E Sternberg
Journal:  Nat Protoc       Date:  2015-05-07       Impact factor: 13.491

View more
  20 in total

1.  Mechanistic Insights to Combating NDM- and CTX-M-Coproducing Klebsiella pneumoniae by Targeting Cell Wall Synthesis and Outer Membrane Integrity.

Authors:  Nicholas M Smith; Katie Rose Boissonneault; Liang Chen; Vidmantas Petraitis; Ruta Petraitiene; Xun Tao; Jieqiang Zhou; Yinzhi Lang; Povilas Kavaliauskas; Zackery P Bulman; Patricia N Holden; Raymond Cha; Jürgen B Bulitta; Barry N Kreiswirth; Thomas J Walsh; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2022-08-04       Impact factor: 5.938

Review 2.  Iron Acquisition Mechanisms and Their Role in the Virulence of Acinetobacter baumannii.

Authors:  Shoshana Cook-Libin; Ellen M E Sykes; Vanessa Kornelsen; Ayush Kumar
Journal:  Infect Immun       Date:  2022-09-06       Impact factor: 3.609

Review 3.  Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance.

Authors:  Stamatis Karakonstantis; Maria Rousaki; Evangelos I Kritsotakis
Journal:  Antibiotics (Basel)       Date:  2022-05-27

Review 4.  Antimicrobial Treatment Options for Difficult-to-Treat Resistant Gram-Negative Bacteria Causing Cystitis, Pyelonephritis, and Prostatitis: A Narrative Review.

Authors:  Andrew Chou; Elwyn Welch; Andrew Hunter; Barbara W Trautner
Journal:  Drugs       Date:  2022-03-14       Impact factor: 11.431

5.  A niclosamide-tobramycin hybrid adjuvant potentiates cefiderocol against P. aeruginosa.

Authors:  Liam Berry; Marc Brizuela; Gregory Jackson; Frank Schweizer
Journal:  RSC Med Chem       Date:  2021-07-27

Review 6.  Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections.

Authors:  Yahiya Y Syed
Journal:  Drugs       Date:  2021-08-24       Impact factor: 9.546

7.  Occurrence of High Levels of Cefiderocol Resistance in Carbapenem-Resistant Escherichia coli before Its Approval in China: a Report from China CRE-Network.

Authors:  Qi Wang; Longyang Jin; Shijun Sun; Yuyao Yin; Ruobing Wang; Fengning Chen; Xiaojuan Wang; Yawei Zhang; Jun Hou; Yumei Zhang; Zhijie Zhang; Liuchun Luo; Zhusheng Guo; Zhenpeng Li; Xin Lin; Lei Bi; Hui Wang
Journal:  Microbiol Spectr       Date:  2022-04-28

8.  Contribution of PER-Type and NDM-Type β-Lactamases to Cefiderocol Resistance in Acinetobacter baumannii.

Authors:  Laurent Poirel; Mustafa Sadek; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2021-07-12       Impact factor: 5.191

9.  Landscape of Multidrug-Resistant Gram-Negative Infections in Egypt: Survey and Literature Review.

Authors:  Amani El-Kholy; Hadir A El-Mahallawy; Noha Elsharnouby; Mohamed Abdel Aziz; Ahmed Mohamed Helmy; Ramy Kotb
Journal:  Infect Drug Resist       Date:  2021-05-24       Impact factor: 4.003

10.  Cefiderocol Activity Against Clinical Pseudomonas aeruginosa Isolates Exhibiting Ceftolozane-Tazobactam Resistance.

Authors:  Patricia J Simner; Stephan Beisken; Yehudit Bergman; Andreas E Posch; Sara E Cosgrove; Pranita D Tamma
Journal:  Open Forum Infect Dis       Date:  2021-06-12       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.